DOPAMINERGIC AGONISTS IMPROVE OBESITY BY ITS ACTION ON LIPID PROFILES AND LEPTIN
Joint Event on International Conference on CELL AND GENE THERAPY & World Congress on CLINICAL AND MEDICAL MICROBIOLOGY
September 10- 11 , 2018 | Dublin , Ireland
Ghada Mohammad Al-Ashmawy, Eman Gouda Khedr and Abla Ebeed
Tanta University, Egypt Delta University, Egypt
Scientific Tracks Abstracts : Biomed Res
Background: The efficacy of a non-prescription drug to support weight loss programs has yet to be compared. This clinical trial investigates the comparability of the lipase inhibitor orlistat and the dopaminergic agonist bromocriptine. Methods: 75 obese females were randomized into three groups according to treatment received; obese control group (OC, n=25), orlistat group (OR, n=25, 120 mg capsules, three times a day) and bromocriptine group (OB, n=25, 20 mg tablet, once a day). This prospective observational study was conducted with norm caloric diet for eight weeks. Serum concentration of leptin and lipid profile were measured, along with Body Mass Index (BMI) at baseline and after the study. Results: Bromocriptine treatment (OB) caused an increase in serum leptin concentration compared to OC and OR groups (ANOVA, p<0.01). Beneficial changes in anthropometric and BMI values were observed following orlistat and bromocriptine administration with the greatest advantage seen in the OB group. Conclusions: Beneficial effects were observed on weight loss, and body composition in all examined groups, with the greatest advantage on serum leptin being associated with the bromocriptine treatment. We find these strategies more promising for the treatment of obesity and its related complications in obese women.
Ghada Al-Ashmawy is currently working in Tanta University, Egypt.